fashion -WSS

fashion

author：entertainment 2025-10-02 08:49:06 - browse：67365

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter:

Novo Nordiskis conducting a large clinical trial to prove that its GLP-1 drug Wegovy, in addition to helping people lose weight, also improves cardiovascular health. The SELECT study enrolled 17,500 participants who had overweight or obesity and had preexisting heart disease. The participants were then randomized to receive weekly injections of Wegovy or a matching placebo. The primary goal is to determine the extent to which Wegovy reduces the risk of heart attacks, strokes, and heart-related deaths. Wegovy is already a blockbuster drug based on weight loss alone, but proving an additional cardiovascular benefit could open the commercial floodgates.

BridgeBiowill report in July an analysis of all-cause mortality from a clinical trial of its heart drug acoramidis. The outcome is an important, second attempt at demonstrating benefit for acoramidis in a progressive heart disease called ATTR-CM. In December 2021, the drug performed no better than a placebo on a test of how far study participants could walk over the course of six minutes, failing to achieve its primary goal. But in this second part of the same study, BridgeBio will determine if acoramidis can significantly reduce hospitalizations and death over the course of 30 months.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： Achieving telehealth equity for people with hearing loss

leisure time

WSS

Medicare Advantage enrollment hits roughly 33.4 million

Unmasking the 'centricity' illusion in clinical trials

Congress: Prevent baby formula shortages by passing a new bill

Hospitals are piloting generative AI tools as regulators play catch

Ozempic cut risk of death in diabetes patients with chronic kidney disease

As AI regulations shape up, health tech startups beg for clarity

hotspot

fashion

focus

How one medical school became remarkably diverse

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

As demand for Covid shots wanes, Moderna seeks its next success

Obamacare plans could cover weight loss drugs

How one medical school became remarkably diverse

Louisiana bill approved classifying abortion pills as controlled substances

Bright Health sells Medicare Advantage business to Molina

The world needs the new pandemic treaty

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

As AI regulations shape up, health tech startups beg for clarity

focus

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

Louisiana bill approved classifying abortion pills as controlled substances

Surprise medical billing ban raises prices elsewhere

Abridge raises $150m as clinical notes automation market heats up

New study raises questions about niacin and heart health

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

hotspot

focus

leisure time

focus